Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.
Expert Rev Pharmacoecon Outcomes Res
; 15(2): 323-30, 2015 Apr.
Article
em En
| MEDLINE
| ID: mdl-25338546
ABSTRACT
INTRODUCTION:
Statins are recommended first-line treatment for hyperlipidemia, with published studies suggesting limited differences between them. However, there are reports of under-dosing. South Africa has introduced measures to enhance generic utilization. Part one documents prescribed doses of statins in 2011. Part two determines the extent of generics versus originator and single-sourced statins in 2011 and their costs.RESULTS:
Underdosing of simvastatin in 2011 with average prescribed dose of 23.7 mg; however, not for atorvastatin (20.91 mg) or rosuvastatin (15.02 mg). High utilization of generics versus originators at 93-99% for atorvastatin and simvastatin, with limited utilization of single-sourced statins (22% of total statins - defined daily dose basis), mirroring Netherlands, Sweden and UK. Generics priced 33-51% below originator prices.DISCUSSION:
Opportunity to increase simvastatin dosing through education, prescribing targets and incentives. Opportunity to lower generic prices with generic simvastatin 96-98% below single-sourced prices in some European countries.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Padrões de Prática Médica
/
Medicamentos Genéricos
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Hiperlipidemias
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Humans
País como assunto:
Africa
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article